As we expected, engineered CRISPR/Cas13d inhibited the mRNA and protein levels of MYC, and thus suppressed cell proliferation, migration, invasion and induced apoptosis of bladder cancer cells in vitro. Here, MYC is linked to urinary bladder cancer.